WO2014071401A1

WO2014071401A1 - Complexes of phosphine ligands comprising a carba-closo-dodecaborate substituent

Info

Publication number: WO2014071401A1
Application number: PCT/US2013/068581
Authority: WO
Inventors: Vincent Lavallo
Original assignee: The Regents Of The University Of California
Priority date: 2012-11-05
Filing date: 2013-11-05
Publication date: 2014-05-08
Also published as: EP2914606B1; EP2914606A4; EP2914606A1; US20150299234A1

Abstract

This invention relates to complexes comprising phosphine ligands comprising a carbo-closo-dodecaborate substituent and transition metals as well as their use in catalytic reactions.

Description

COMPLEXES OF PHOSPHINE LIGANDS COMPRISING A C ARB A- CLOSO-DODECABORATE SUBSTITUENT

CROSS-REFERENCES TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application Serial Number 61/722,740, filed 5 November 2012, the entire contents of which are herein incorporated by reference in its entirety for all purposes.

FIELD OF THE INVENTION

[0002] This invention relates to transition metal catalysts and their use in catalytic reactions such as, but not limited to, olefin polymerization.

BACKGROUND OF THE INVENTION

[0003] Modern transition metal catalysis is based, in part, on metal complexes that include a diverse range of ligand frameworks, such as bulky R-groups which influence the catalytic activity of these complexes. These types of sterically demanding ligands kinetically protect the active metal center and promote substrate exchange and low coordination, both of which are necessary processes for high turnover numbers (TON). These ligands also influence the metal center's selectivity for product formation and substrate consumption. Of the many ligands used in modern metal catalysis, dicarba-closo-dodecaborane (C₂B₁₀) clusters (M. Scholz, et al, Chem. Rev. 2011, 1 1 1, 7035-7062; N. Fey, et al, Organometallics 2012, 31, 2907-2913; A. M. Spokoyny, et al, Nature Chem. 201 1, 3, 590-596; J. I. van der Vlugt, Angew. Chem. 2010, 122, 260-263; Angew. Chem. Int. Ed. 2010, 49, 252-255) are not commonly used. These boron containing ligands have not been employed much in the relevant field because of potential negative side reactions, such as B-H activation and cyclometalation. For these and related reasons, such as intramolecular reactions, the synthetic utility of carborane bearing ligands in the area of catalysis has been limited.

[0004] Complexes that contain ligands functionalized with related carba-closo- dodecaborate anions (CBn ) directly bound to the coordinating atom via the carborane hypercarbon have not been reported (S. K5rbe, et al., Chem. Rev. 2006, 106, 5208-5249). Although similar in size to their neutral dicarba-cousins (C₂B₁₀), isoelectronic (CBn-) clusters have significantly different properties. The negative charge of these clusters is delocalized throughout the 12 cage atoms, resulting in a very weakly coordinating anion. This weak coordinative ability can be enhanced by substitution of some or all of the B-H vertices by alkyl or halo-groups. In the case of alkyl substitution, the cluster becomes more reactive towards substitution and oxidation chemistry. On the other hand, exhaustive halogenation of the cluster's boron vertices introduces electron withdrawing substituents that enhance the anion's inherent weak coordinative ability and also confers these molecules with inertness to certain chemicals and reactions. For example, some perhalogenated carborane counteranions are observed to form isolable salts with potent oxidants such as C₆o⁺ and CH₃ ⁺.

[0005] There is currently a need, for example, for single component gold catalysts which offer a number of advantages compared to traditional two component systems that utilize Ag⁺ or strong Bronsted acid additives. These additives not only increase the cost of the systems, but can also induce side reactions or different reactivity all together. Accordingly, there exists a need in the field to which the instant invention relates regarding the development and use of novel bulky ligands and their associated transition metal complexes. Surprisingly, the instant invention meets these as well as other needs in the relevant field.

BRIEF SUMMARY OF THE INVENTION

[0006] In one embodiment, the instant application sets forth a composition comprising a transition metal and at least one ligand comprising a carba-closo-dodecaborate substituent.

[0007] In a second embodiment, the instant application sets forth a ligand having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. A is a cation. For example, A may include Li, Na, K, Cs, HN(alkyl)3, or N(alkyl). [0008] In a third embodiment, the instant application sets forth a zwitterionic complex having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. X¹ is selected from H, alkyl, or aryl. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal.

[0009] In a fourth embodiment, the instant application sets forth a zwitterionic complex having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected alkyl, aryl, or alkoxy. X¹ is of H, alkyl, or aryl. Q is a chelating ligand. M is a transition metal

[0010] In a fifth embodiment, the instant application sets forth an anionic complex having the following structure:

R¹ is H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. X¹ is H, alkyl, or aryl. X² is an anion selected from H, halide, alkyl, or aryl. A is a cation. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal.

[0011] In a sixth embodiment, the instant application sets forth an anionic complex having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. X¹ is selected from H, alkyl, or aryl. X² is an anion selected from H, halide, alkyl, or aryl. Q is a chelating ligand. A is a cation. M is a transition metal.

[0012] In a seventh embodiment, the instant application provides a zwitterionic complex having the following structure:

R¹ is H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal. [0013] In an eighth embodiment, the instant application provides a zwitterionic complex having the following structure:

R¹ is H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. M is a transition metal.

[0014] In a ninth embodiment, the instant application provides an anionic complex having the following structure:

R¹ is H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. A is a monopositively charged cation or a dipositively charged cation. Subscript y is either 1 or 2. M is a transition metal.

[0015] In a tenth embodiment, the instant application provides a methods of catalyzing chemical reactions, wherein the chemical reactions include, but are not limited to, olefin polymerization, hydroaddition, hydroamination, cross coupling, olefin metathesis hydroformylation, hydrogenation, hydroaminomethylation. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 shows a synthetic procedure for preparing a phosphine ligand containing a carba-closo-dodecaborate ligand substituent in accordance with the present invention.

[0017] Figure 2 shows a solid state structure of an phosphine ligand containing a carba- closo-dodecaborate ligand substituent 2, wherein the hydrogen atoms are omitted for clarity. Thermal ellipsoids drawn at the 50% probability level.

[0018] Figure 3 shows the synthesis of complexes 3(THT) and 3(LiCl), top left and right respectively. Solid state structure of 3(THT), bottom left. Solid state structure of 3(LiCl), bottom right. Selected bond lengths for 3(LiCl); P-Au = 2.2477(12), P-Cl = 1.943(5), P-C2 = 1.858(6), P-C3 = 1.864(5), Au-Cl = 2.2883(12). Bond lengths in A, thermal ellipsoids drawn at the 50% probability level, hydrogen atoms in both 3(THT) and 3(LiCl) omitted for clarity.

[0019] Figure 4 shows non-limiting examples of the types of reactions which the compounds of the instant invention are suitable for catalyzing.

[0020] Figure 5 shows an example of Boron NMR.

[0021] Figure 6 shows a synthetic procedure for preparing a ligand suitable for use in a complex with a transition metal.

[0022] Figure 7 shows ^XH NMR data for the complex illustrated therein. [0023] Figure 8 shows ³¹P NMR data for the complex illustrated therein. [0024] Figure 9 shows ¹³C NMR data for the complex illustrated therein.

[0025] Figure 10 shows ⁿB NMR data for the complex illustrated therein.

[0026] Figure 1 1 shows a solid state structure of a phosphine complex.

[0027] Figure 12 Figure 2 shows a solid state structure of a phosphine Au complex.

[0028] Figure 13 shows a synthetic procedure for preparing a Au complex.

[0029] Figure 14 shows ^XH NMR data for the complex illustrated therein.

[0030] Figure 15 shows ³¹P NMR data for the complex illustrated therein.

[0031] Figure 16 shows ¹³C NMR data for the complex illustrated therein.

[0032] Figure 17 shows ⁿB NMR data for the complex illustrated therein.

[0033] Figure 18 shows example reactions suitable for catalysis by Au complexes. [0034] Figure 19 shows hydroamination of alkynes results observed using catalysts of the present invention.

[0035] Figure 20 shows hydroamination of alkynes results observed using catalysts of the present invention.

[0036] Figure 21 shows an example of olefin polymerization.

[0037] Figure 22 shows an example of olefin polymerization.

[0038] Figure 23 shows an example of olefin polymerization.

DETAILED DESCRIPTION OF THE INVENTION GENERAL

[0039] The present invention provides complexes, such as zwitterionic iridium complex of a phosphine bearing carba-c/osododecaborate anion ligand substituents. The present invention also provides methods of making these complexes as well as methods of using these complexes as catalysts.

[0040] Whereas as other catalysts suffer from a variety of disadvantages, the instant compounds and complexes advantageously include ligands with very stable and unreactive 3- dimensionally anionic carborane clusters. The instant compounds and complexes are less likely to be made inactive during catalysis compared to standard catalysts that feature ligands with only hydrocarbon substituents.

DEFINITIONS

[0041] As used herein, the term "zwitterionic" or "zwitterion" refers to a neutrally charged compound having both positive and negative charged groups therein.

[0042] As used herein, the term "halide," refers to an anion of F, CI, Br, or I. "Halogen" as used herein includes F, CI, Br, or I.

[0043] As used herein, the term "alkyl," refers to a hydrocarbon group derived from an alkane by removing one hydrogen atom. Examples of alkyl include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, n-butyl, t-butyl, isopentyl, and n-pentyl. Alkyl can include any alkyl group having from about 1 to about 16 carbon atoms.

[0044] As used herein, the term "alkoxy" refers to a group having the formula -O-R, wherein R is alkyl or aryl. [0045] As used herein, the term "aryl" refers to a substituent derived from an aromatic compound by removing one hydrogen atom. Examples of aryl include, but are not limited to, phenyl, mesityl, 2,6,-diisopropylphenyl, napthyl, and benzyl.

[0046] As used herein, the term "leaving group," refers to group that is displaced by a nucleophile. Examples include, but are not limited to, halides and sulfonate esters, e.g., tosylate.

[0047] As used herein, chelating refers to a ligand that bonds to a metal center through more than one bond. Examples include bidentate and tridentate chelating ligands such as, but not limited to, EDTA and citric acid.

[0048] As used herein, the term "phosphine ligand," refers to a ligand that includes a phosphine bond. In the relevant field to which the instant invention pertains, phosphines are derivatives of P¾ in which one, two or three hydrogens are replaced by, for example, alkyl or aryl substituents. Examples of phosphines include, but are not limited to,

triphenylphosphine.

[0049] As used herein, the term "silyl" refers to a group having the formula -S1-R3, wherein R is alkyl or aryl.

[0050] As used herein, the term "carba-closo-dodecaborate substituent" refers to a compound having the following formula -CBUR ^"1 where the carbon atom is attached to a phosphine ligand as depicted below:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently alkyl, aryl, or alkoxy. A is a cation [e.g., Li, Na, K, Cs, HN(alkyl)₃, or N(alkyl)]. COMPLEXES

[0051] In certain embodiments, the present invention further provides compounds and complex, e.g., zwitterionic iridium complex of a phosphine comprising the caxba-closo- dodecaborate anion as a ligand substituent. In some embodiments, when the transition metal, e.g., iridium, is bonded directly to a phosphine ligand, the CBnHn^" R^" group engages in agostic-like bonding, utilizing the B-H bonds adjacent to the carbon atom in the cluster. Evidence for the interactions is observed in solution by variable temperature NMR and also in the solid state by a single crystal X-ray diffraction study. A significant lengthening of a tmns-olefm C-C bond suggests this ligand substituent has a pronounced iraws-influence, which is in contrast to the unfunctionalized weakly coordinating HCBnHn^" anion.

[0052] In some embodiments, the instant application provides a composition including a transition metal and at least one ligand that includes at least 1 carba-closo-dodecaborate substituent.

[0053] In certain embodiments, the instant application provides a ligand having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. A is a cation. In certain embodiments, A is selected from Li, Na, K, Cs, HN(alkyl)₃, or (alkyl)₄.

[0054] In some embodiments of the above formula, R¹ is H. In other embodiments R¹ is F. In some other embodiments, R¹ is CI. In other embodiments, R¹ is Br. In certain

embodiments, R¹ is methyl. In other embodiments, R¹ is ethyl. In some embodiments, R¹ is propyl (e.g., n-propyl, i-propyl). In other embodiments R¹ is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R¹ is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other embodiments, R¹ is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R¹ is octyl. In other embodiments, R¹ is nonyl. In yet others, R¹ is dodecyl. [0055] In some embodiments of the above formula, R¹ is phenyl, benzyl, or napthyl. In other embodiments R¹ is phenyl. In some other embodiments, R¹ is benzyl. In other embodiments, R¹ is napthyl. In certain embodiments, R¹ is tolulyl. In other embodiments, R¹ is methoxy. In some embodiments, R¹ is ethoxy. In other embodiments R¹ is propoxy. In some other embodiments, R¹ is butoxy. In other embodiments, R¹ is trimethylsilyl. In certain embodiments, R¹ is triethylsilyl.

[0056] In certain embodiments, R² is methyl. In other embodiments, R² is ethyl. In some embodiments, R² is propyl (e.g., n-propyl, i-propyl). In other embodiments R² is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R² is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other embodiments, R² is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R² is octyl. In other embodiments, R² is nonyl. In yet others, R² is dodecyl.

[0057] In some embodiments of the above formula, R² is phenyl, benzyl, or napthyl. In other embodiments R² is phenyl. In some other embodiments, R² is benzyl. In other embodiments, R² is napthyl. In certain embodiments, R² is tolulyl. In other embodiments, R² is methoxy. In some embodiments, R² is ethoxy. In other embodiments R² is propoxy. In some other embodiments, R² is butoxy. In some embodiments, R² is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R² is dimethylamino or diethylamino.

[0058] In certain embodiments, R³ is methyl. In other embodiments, R³ is ethyl. In some embodiments, R³ is propyl (e.g., n-propyl, i-propyl). In other embodiments R³ is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R³ is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other embodiments, R³ is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R³ is octyl. In other embodiments, R³ is nonyl. In yet others, R³ is dodecyl.

[0059] In some embodiments of the above formula, R³ is phenyl, benzyl, or napthyl. In other embodiments R³ is phenyl. In some other embodiments, R³ is benzyl. In other embodiments, R³ is napthyl. In certain embodiments, R³ is tolulyl. In other embodiments, R³ is methoxy. In some embodiments, R³ is ethoxy. In other embodiments R³ is propoxy. In some other embodiments, R³ is butoxy. In some embodiments, R³ is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R³ is dimethylamino or diethylamino.

[0060] In some embodiments, the halogen is selected from F, CI, Br, or I. [0061] In some embodiments, the ligand has the following structure:

[0062] In some other embodiments, the present application provides a zwitterionic complex having the following structure:

R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. X¹ is selected from H, alkyl, or aryl. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal.

[0063] In certain embodiment set forth herein, n is 1. In certain other embodiment set forth herein, n is 2. In some embodiment set forth herein, n is 3. In certain embodiment set forth herein, n is 4. In certain embodiment set forth herein, n is 5. In certain embodiment set forth herein, n is 6.

[0064] In some embodiments, M is selected from Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In other embodiments, M is selected from Fe, Ru, Co, Ni, or Pd. [0065] In some embodiments of the above formula, R¹ is H. In other embodiments R¹ is F. In some other embodiments, R¹ is CI. In other embodiments, R¹ is Br. In certain

embodiments, R¹ is methyl. In other embodiments, R¹ is ethyl. In some embodiments, R¹ is propyl (e.g., n-propyl, i-propyl). In other embodiments R¹ is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R¹ is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other

embodiments, R¹ is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R¹ is octyl. In other embodiments, R¹ is nonyl. In yet others, R¹ is dodecyl.

[0066] In some embodiments of the above formula, R¹ is phenyl, benzyl, or napthyl. In other embodiments R¹ is phenyl. In some other embodiments, R¹ is benzyl. In other embodiments, R¹ is napthyl. In certain embodiments, R¹ is tolulyl. In other embodiments, R¹ is methoxy. In some embodiments, R¹ is ethoxy. In other embodiments R¹ is propoxy. In some other embodiments, R¹ is butoxy. In other embodiments, R¹ is trimethylsilyl. In certain embodiments, R¹ is triethylsilyl.

[0067] In certain embodiments, R² is methyl. In other embodiments, R² is ethyl. In some embodiments, R² is propyl (e.g., n-propyl, i-propyl). In other embodiments R² is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R² is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other embodiments, R² is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R² is octyl. In other embodiments, R² is nonyl. In yet others, R² is dodecyl.

[0068] In some embodiments of the above formula, R² is phenyl, benzyl, or napthyl. In other embodiments R² is phenyl. In some other embodiments, R² is benzyl. In other embodiments, R² is napthyl. In certain embodiments, R² is tolulyl. In other embodiments, R² is methoxy. In some embodiments, R² is ethoxy. In other embodiments R² is propoxy. In some other embodiments, R² is butoxy. In some embodiments, R² is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R² is dimethylamino or diethylamino.

[0069] In certain embodiments, R³ is methyl. In other embodiments, R³ is ethyl. In some embodiments, R³ is propyl (e.g., n-propyl, i-propyl). In other embodiments R³ is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R³ is pentyl (n-pentyl, i-pentyl , cyclopentyl). In other embodiments, R³ is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R³ is octyl. In other embodiments, R³ is nonyl. In yet others, R³ is dodecyl.

[0070] In some embodiments of the above formula, R³ is phenyl, benzyl, or napthyl. In other embodiments R³ is phenyl. In some other embodiments, R³ is benzyl. In other embodiments, R³ is napthyl. In certain embodiments, R³ is tolulyl. In other embodiments, R³ is methoxy. In some embodiments, R³ is ethoxy. In other embodiments R³ is propoxy. In some other embodiments, R³ is butoxy. In some embodiments, R³ is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R³ is dimethylamino or diethylamino.

[0071] In some embodiments, the present application provides a zwitterionic complex having the following structure:

[0072] R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. X¹ is selected from the group consisting of H, alkyl, or aryl. Q is a chelating ligand; and M is a transition metal. The complex may further comprising 1 to 2 additional Q chelating ligands bonded to M. In any embodiment, M is selected from Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In some embodiments, M is selected from Fe, Ru, Co, Ni, or Pd.

[0073] In some embodiments, the present application provides an anionic complex having the following structure:

[0074] R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. X¹ is selected from H, alkyl, or aryl. X² is an anion selected from H, halide, alkyl, or aryl. A is a cation. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal. In some embodiments, M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In other embodiments, M is selected from the group consisting of Fe, Ru, Co, Ni, or Pd.

[0075] In some embodiments, the present application provides an anionic complex having the following structure:

[0076] R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. X¹ is selected from H, alkyl, or aryl. X² is an anion selected from H, halide, alkyl, or aryl. Q is a chelating ligand. A is a cation. M is a transition metal. The complex may further comprise 1 to 2 additional Q ligands bonded to M. A is cation. For example, A may be selected from Li, Na, K, Cs, FTN(alkyl)3, or N(alkyl)₄. M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. M is selected from the group consisting of Fe, Ru, Co, Ni, or Pd.

[0077] In some embodiments, the present application provides a zwitterionic complex having the following structure:

[0078] R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. L is neutral ligand. Subscript n is an integer selected from 1, 2, 3, 4, 5, or 6. M is a transition metal. In some embodiments, M is selected from Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In other embodiments, M is selected from Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au.

[0079] In some preferred embodiments, L is CI. In other embodiments, L is

tetrahydrothiophene.

[0080] In some embodiments, the present application provides a zwitterionic complex having the following structure:

[0081] R is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R and R are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. M is a transition metal. In some embodiments, M is selected from Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In other embodiments, M is selected from Ni, Pd, or Cu. In some of these embodiments, M is in either a +2 or +4 oxidation state.

[0082] In some embodiments, the present application provides an anionic complex having the following structure:

[0083] R¹ is selected from H, halogen, alkyl, aryl, silyl, or alkoxy. R² and R³ are each independently selected from alkyl, aryl, alkoxy, or NR⁴R⁵. R⁴ and R⁵ are each independently selected from alkyl, aryl, or alkoxy. A is a monopositively charged cation or a dipositively charged cation. Y is 1 or 2. M is a transition metal. In some embodiments, M is selected from Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, or Au. In other embodiments, M is selected from Ni, Pd, or Cu. In certain embodiments, M is in either a +2 or +4 oxidation state.

[0084] In some embodiments, the present application provides a complex having the following structure:

[0085] In some embodiments of the above formula, R¹ is H. In other embodiments R¹ is F. In some other embodiments, R¹ is CI. In other embodiments, R¹ is Br. In certain

[0086] In any of the above embodiments, R¹ is phenyl, benzyl, or napthyl. In other embodiments R¹ is phenyl. In some other embodiments, R¹ is benzyl. In other embodiments, R¹ is napthyl. In certain embodiments, R¹ is tolulyl. In other embodiments, R¹ is methoxy. In some embodiments, R¹ is ethoxy. In other embodiments R¹ is propoxy. In some other embodiments, R¹ is butoxy. In other embodiments, R¹ is trimethylsilyl. In certain embodiments, R¹ is triethylsilyl.

[0087] In certain of the above embodiments, R² is methyl. In other embodiments, R² is ethyl. In some embodiments, R² is propyl (e.g., n-propyl, i-propyl). In other embodiments R² is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R² is pentyl (n-pentyl, i- pentyl , cyclopentyl). In other embodiments, R² is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R² is octyl. In other embodiments, R² is nonyl. In yet others, R² is dodecyl.

[0088] In some of the above embodiments of the above formula, R² is phenyl, benzyl, or napthyl. In other embodiments R² is phenyl. In some other embodiments, R² is benzyl. In other embodiments, R² is napthyl. In certain embodiments, R² is tolulyl. In other embodiments, R² is methoxy. In some embodiments, R² is ethoxy. In other embodiments R² is propoxy. In some other embodiments, R² is butoxy. In some embodiments, R² is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R² is dimethylamino or

diethylamino.

[0089] In certain of the above embodiments, R³ is methyl. In other embodiments, R³ is ethyl. In some embodiments, R³ is propyl (e.g., n-propyl, i-propyl). In other embodiments R³ is butyl (e.g., n-butyl, i-butyl). In some other embodiments, R³ is pentyl (n-pentyl, i- pentyl , cyclopentyl). In other embodiments, R³ is hexyl (n-hexyl, cyclohexyl). In certain embodiments, R³ is octyl. In other embodiments, R³ is nonyl. In yet others, R³ is dodecyl.

[0090] In some of the above embodiments of the above formula, R³ is phenyl, benzyl, or napthyl. In other embodiments R³ is phenyl. In some other embodiments, R³ is benzyl. In other embodiments, R³ is napthyl. In certain embodiments, R³ is tolulyl. In other embodiments, R³ is methoxy. In some embodiments, R³ is ethoxy. In other embodiments R³ is propoxy. In some other embodiments, R³ is butoxy. In some embodiments, R³ is NR⁴R⁵, wherein R⁴ and R⁵ are independently selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and nonyl. In certain embodiments, R³ is dimethylamino or

diethylamino.

[0091] In some of the above embodiments, L is a neutral ligand selected from

cyclooctadiene.

[0092] In certain preferred embodiments of the above, R² and R³ are isopropyl. [0093] Certain Preferred Substituents include the following.

[0094] In some of the above embodiments, preferred R¹ groups include, but are not limited to carborane H, F, CI, Br, I, benzene, methyl, ethyl, n-propyl, n-butyl, methoxy,eEthoxy, n- propoxy , n-butyloxy, or trimethylsiloxy. [0095] In some of the above embodiments, preferred R² groups include benzene, naphthyl, Mesityl, 2,6-diisopropylphenyl, Tolyl, or -C₆F5. In some of the above embodiments, preferred R² groups include methyl, ethyl, propyl, butyl, isopropyl, t-butyl, adamantly, cyclohexyl, or cyclopentyl. In some of the above embodiments, preferred R² groups include methoxy, ethoxy, propoxy , butyloxy, isopropoxy, t-butoxy, phenoxy, or mesityloxy. In some of the above embodiments, preferred R² groups include Trimethylsiloxy, triethyl siloxy, or tripropyl siloxy.

[0096] In some of the above embodiments, preferred R⁴ and R⁵ include H. In other preferred embodiments, R⁴ and R⁵, independently, include benzene, naphthyl, Mesityl, 2,6- diisopropylphenyl, Tolyl, or -C₆F5. In other preferred embodiments, R⁴ and R⁵ include, independently, methyl, ethyl, propyl, butyl, isopropyl, t-butyl, adamantly, cyclohexyl, or cyclopentyl. In other preferred embodiments, R⁴ and R⁵ include trimethylsilyl, triethylsilyl, or tributylsilyl.

[0097] In some preferred embodiments, R² or R³ are independently selected from NR⁴R⁵, wherein R⁴ and R⁵ are H, benzene, naphthyl, Mesityl, 2,6-diisopropylphenyl, Tolyl, -C₆F5, methyl, ethyl, propyl, butyl, isopropyl, t-Butyl, adamantly, cyclohexyl, cyclopentyl, trimethylsilyl, triethylsilyl, or tributylsilyl.

[0098] In some preferred embodiments, X¹ and X² are independently selected from NR⁴R⁵, wherein NR⁴R⁵ is imido. In some embodiments, R⁴ and R⁵ are N-Alkyl, NAryl, Sulfido S-R, or Phosphido P-R.

[0099] In some of the above embodiments, preferred R³ groups include benzene, naphthyl, Mesityl, 2,6-diisopropylphenyl, Tolyl, or -C₆F5. In some of the above embodiments, preferred R³ groups include methyl, ethyl, propyl, butyl, isopropyl, t-butyl, adamantly, cyclohexyl, or cyclopentyl. In some of the above embodiments, preferred R³ groups include methoxy, ethoxy, propoxy , butyloxy, isopropoxy, t-butoxy, phenoxy, or mesityloxy. In some of the above embodiments, preferred R³ groups include Trimethylsiloxy, triethyl siloxy, or tripropyl siloxy.

[0100] In other preferred embodiments, L is a neutral ligand. In some embodiments, L is a solvent molecule selected from dimethoxy ethane, dioxane, pyridine, tetrahydrofuran, diethyl ether, benzene, toluene, acetonitrile, methylene chloride, chloroform, dimethyl formamide, or acetone. In other preferred embodiments, L is a phosphine (PR₃) containing three alkyl or aryl groups, A phosphite (P(OR)₃), P( R₂)₃, a carbene, N-heterocyclic carbene, an alkylidene carbene, a benzylidene carbene, an olefin, an alkyne, a diene, an enone, a polyene, a sulfide (SR₂), an alcohol, a ketone, or an ester.

I _|_ _|_ _|_ ₂"_!" ₂ I

[0101] In some preferred embodiments, A is selected firm Li , Na , K , Cs , Mg , Ca , Zn²⁺, NH₄ ⁺, HN(Alkyl)₃ ⁺, HN(Me)₃ ⁺ , HN(Ethyl)₃ ⁺,HN(Butyl)₄ ⁺, HN(Aryl)₃ ⁺, H₂N(Alkyl)₂ ⁺, H₃NAlkyl⁺, H₃NAryl⁺, a transition metal cation, a main group cation, an alkaline earth cation, or a polyatomic cation.

[0102] In some preferred embodiments, X¹ and X² are independently selected from H, F, CI, Br, I. In some preferred embodiments, X¹ and X² are independently selected from methyl, ethyl, propyl, butyl, isopropyl, t-Butyl, adamantly, cyclohexyl, cyclopentyl, neopentyl,-CH₂SiMe₃, benzyl.

[0103] In some preferred embodiments, X¹ and X² are independently selected from -C₆H5, naphthyl, Mesityl, or Tolyl.

[0104] In some preferred embodiments, X¹ and X² are independently selected from methoxy, ethoxy, propoxy , butyloxy, isopropoxy, t-butoxy, phenoxy, or mesityloxy.

[0105] In some preferred embodiments, X¹ and X² are independently selected from

Trimethylsiloxy, triethyl siloxy, or tripropyl siloxy).

[0106] In some preferred embodiments, X¹ and X² are independently selected from NR⁴R⁵, wherein R⁴ and R⁵ are H, benzene, naphthyl, Mesityl, 2,6-diisopropylphenyl, Tolyl, -C₆F5, methyl, ethyl, propyl, butyl, isopropyl, t-Butyl, adamantly, cyclohexyl, cyclopentyl, trimethylsilyl, triethylsilyl, or tributylsilyl.

[0107] In some preferred embodiments, X¹ and X² are independently selected from NR⁴R⁵, wherein NR⁴R⁵ is imido. In some embodiments, R⁴ and R⁵ are N-Alkyl, NAryl, Sulfido S-R, or Phosphido P-R.

METHOD OF MAKING COMPOUNDS AND COMPLEXES

[0108] In some embodiments, the present invention provides methods of making ligands having the following general formula:

In these embodiments, R¹ is selected from the group consisting of H, halide, alkyl, aryl, silyl, and alkoxy. R² and R³ are each independently selected from the group consisting of alkyl, aryl, alkoxy, and NR⁴R⁵. In these embodiments, R⁴ and R⁵ are each independently selected from the group consisting of alkyl, aryl, and alkoxy. In any embodiment set forth herein, halide includes a member selected from the group consisting of fluoride, chloride, bromide, and iodide. A⁺ represents a counter-cation. In some embodiments, A is selected from the group consisting of Li⁺, Na⁺, K⁺, Cs⁺, HN(alkyl)₃ ⁺, and N(alkyl)₄ ⁺. Other suitable cations may include, but are not limited to a member selected from the group consisting of Be²⁺, Mg²⁺, Ca²⁺, Sr^, and Ba²⁺.

[0109] In some embodiments, the methods of making the ligands used herein include providing a solution of a C-H carba-c/oso-dodecaborate anion, having the following formula, in THF:

[0110] In certain embodiments, the methods further include treating the anion with 1-3 equivalents of a base, wherein the base is w-BuLi (i.e., n-butyl lithium). In some

embodiments, the methods then include stirring for about three hours. In some embodiments, the methods further include concentrating the reaction under high vacuum. In some of these embodiments, the methods include washing the resulting residue with dry hexane to prepare a solid. In some embodiments, the methods include dissolving the solid in THF or F-C₆H₅ and treating it with 1.1 equivalents of the X-P(R²)(R³) reagent. In some embodiments, the methods include stirring the reaction until completion. In certain embodiments, completion is determined by P NMR analysis. In some embodiments, the methods include concentrating the mixture to dryness, washing the concentrate with hexane. In some embodiments, the methods include including the solid residue ( i.e., the phosphine ligand) extracted in a solvent, wherein the solvent includes, but is not limited to CHCI₃, CH2CI2, F-C₆H5). In some of these embodiments, the salt byproducts do not dissolve in the solvent. In some embodiments, the methods include filtering the mixture and drying the solution to afford the desired phosphine in about 95-100% yield.

[0111] In some embodiments, the present invention provides methods illustrated by the following reaction scheme:

[0112] In any of the embodiments set forth herein, X refers to a leaving group. In some of these embodiments, the leaving group is selected from the group consisting of CI, Br, and I.

[0113] In some embodiments, the present inventions provides methods of making ligands that include, but are not limited to the following synthesis. A solution of the C-H carba- c/oso-dodecaborate anion in THF is treated with 1 -3 equivalents of a base (preferably n- BuLi) and stirred for 3 hours and subsequently concentrated under high vacuum. The residue is thoroughly washed with dry hexane and the solid is subsequently dissolved in THF or F- C₆H5 and treated with 1.1 equivalents of the desired X-P(R²)(R³) reagent and the reaction is stirred until completion is determined by ³¹P NMR analysis. The mixture is subsequently concentrated to dryness, washed with hexane, and the solid residue containing the phosphine ligand extracted with a solvent ( e.g. CHC13, CH2CI2, F-C₆H5) where the salt byproducts do not dissolve. The mixture is filtered and the solution is concentrated to dryness to afford the desired phosphine in 95-100% yield.

CATALYTIC REACTIONS

[0114] The instant application sets forth methods of catalyzing chemical reactions, wherein the methods include contacting a complex, set forth herein, with suitable reagents for the chemical reaction to occur. In some embodiments, the chemical reaction catalyzed is olefin polymerization. In some other embodiments, the chemical reaction catalyzed is

hydroamination. In some other embodiments, the chemical reaction catalyzed is cross coupling. In some other embodiments, the chemical reaction catalyzed is hydrogenation.

[0115] The literature describing Au-based catalysts includes a) H. Schmidbaur, et al, B: J. Chem. Sci. 2011, 66, 329-350; Synthesis (Eds.: A.S.K. Hashmi, F. D. Toste), Wiley-VCH, Weinheim, 2012; A. Gomez-Suarez, et al, Angew. Chem. 2012, 124, 8278-8281; Angew. Chem. Int. Ed. 2012, 51, 8156-8159; C. C. J. Loh, et al, Chem. Eur. J. 2012, 18, 10212- 10225; D. Garayalde, et al, ACS Catal. 2012, 2, 1462-1479; D. Wang, et al, J. Am. Chem. Soc. 2012, 134, 9012-9019; f) B.-L. Lu, L. Dai, M. Shi, Chem. Soc. Rev. 2012, 41, 3318- 3339; L.-P. Liu, et al, Chem. Soc. Rev. 2012, 41, 3129-3139; M. Rudolph, et al, Chem. Soc. Rev. 2012, 41, 2448-2462; C. D. Pina et al, Chem. Soc. Rev. 2012, 41, 350-369; M.

Rudolph, et al, Chem. Commun. 201 1, 47, 6536-6544; M. Bandini, Chem. Soc. Rev. 2011, 40, 1358-1367; M. Malacria, , Top. Curr. Chem. 201 1, 302, 157-182; A. S. K. Hashmi, Angew. Chem. 2010, 122, 5360-5369; Angew. Chem. Int. Ed. 2010, 49, 5232-5241 ; D. J. Gorin, et al, Chem. Rev. 2008, 108, 3351-3378.

[0116] The literature describing hydroamination reactions includes J. L. Klinkenberg, et al, Angew. Chem. 2011, 123, 88-98; Angew. Chem. Int. Ed. 2011, 50, 86-95; I. Krossing, Angew. Chem. 201 1, 123, 1 1781-1 1783; Angew. Chem. Int. Ed. 2011, 50, 11576-11578; T. E. Muller, et al, Chem. Rev. 2008, 108, 3795-3892; R. A. Widenhoefer, et al, Eur. J. Org. Chem. 2006, 2006, 4555-4563.

[0117] The literature describing gold catalyzed hydroamination of alkynes includes S. Fleischer, et al, Chem. Eur. J. 2012, 18, 9005-9010; E. Alvarado, et al, Chem. Eur. J. 2012, 18, 121 12-12121; R. Kinjo, et al, Angew. Chem. 201 1, 123, 5674-5677; Angew. Chem. Int. Ed. 2011, 50, 5560-5563; K. L. Butler, et al, Angew. Chem. 2012, 124, 5265-5268; Angew. Chem. Int. Ed. 2012, 51, 5175-5178; K. D. Hesp, et al, J. Am. Chem. Soc. 2010, 132, 18026- 18029; A. Leyva-Perez, et al, J. Org. Chem. 2010, 75, 7769-7780; V. Lavallo, et al, Angew. Chem. 2008, 120, 5302-5306; Angew. Chem. Int. Ed. 2008, 47, 5224-5228; E. Mizushima, et al, Org. Lett. 2003, 5, 3349-3352)

[0118] In some embodiments, the instant application provides methods of catalyzing olefin polymerization reactions comprising contacting a complex described herein with suitable olefin polymerization reagents. [0119] In some embodiments, the instant application provides methods of catalyzing hydroaddition reactions comprising contacting a complex described herein with suitable hydroaddition reagents.

[0120] In some embodiments, the instant application provides methods of catalyzing hydroamination reactions comprising contacting a complex described herein with suitable hydroamination reagents.

[0121] In some embodiments, the instant application provides methods of catalyzing cross coupling reactions contacting a complex described herein with suitable cross coupling reagents.

[0122] In some embodiments, the instant application provides methods of catalyzing olefin metathesis reactions comprising contacting a complex described herein with suitable olefin metathesis reagents.

[0123] In some embodiments, the instant application provides methods of catalyzing hydroformylation reactions comprising contacting a complex described herein with suitable hydroformylation reagents.

[0124] In some embodiments, the instant application provides methods of catalyzing hydrogenation reactions comprising contacting a complex described herein with suitable hydrogenation reagents.

[0125] In some embodiments, the instant application provides methods of catalyzing hydroaminomethylation reactions comprising contacting a complex described herein with suitable hydroaminomethylation reagents.

EXAMPLES

[0126] Example 1 - Synthesis of Ligands

[0127] A solution of the C-H carba-c/oso-dodecaborate anion in THF was treated with 1-3 equivalents of a base (most preferably w-BuLi) and stirred for 3 hours and subsequently concentrated under high vacuum. The residue was thoroughly washed with dry hexane and the solid was subsequently dissolved in THF or F-C₆H₅ and treated with 1.1 equivalents of the desired X-P(R2)(R3) reagent and the reaction was stirred until completion was determined by ³¹P NMR analysis. The mixture was subsequently concentrated to dryness, washed with hexane, and the solid residue containing the phosphine ligand extracted with a solvent ( e.g. CHC13, CH2C12, F-C6H5) where the salt byproducts do not dissolve. The mixture was filtered and the solution was concentrated to dryness to afford the desired phosphine in 95-100% yield.

[0128] Ligands synthesized by this method include the following examples:

[0129] iPr₂PCB_nClif Li⁺ (x 4 THF); ³¹P-(1H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =77.3 ppm

[0130] iPr₂PCBnH5Cl₆ ^" Li⁺ (x 4 THF); ³¹P-(1H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =86.6 ppm

[0131] iPrzPCBnHn^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ = 45.4 ppm

[0132] iPrzPCBnHn^" N(Butyl₄)⁺; ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =45.6 ppm

[0133] iPrzPCBnHn^" N(Me₄)⁺; ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =45.6 ppm

[0134] iPrzPCBnBrn^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =100.2 ppm

[0135] iPr₂PCB_nH₅Br₆ ^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =95.0 ppm

[0136] PhzPCBnBrn^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ = 106.6 ppm

[0137] Ph₂PCBiiCl_u ^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ = 87.8 ppm

[0138] Et₂PCBiiBrn^" Li⁺ (x 4 THF); ³¹P-(¹H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C) δ =99.7 ppm

[0139] Example 2 - Synthesis of a Catalyst

[0140] This catalyst is suitable for use in, for example, olefin polymerization

[0141] A solution of the phosphine ligand iPr₂PCBnCln^" Li (x 4 THF) (1 mmol, 933.421 mg) was dissolved in 20 mL FC₆H₅ and reacted with a solution of (ClPdAllyl)₂ (0.5 mmol 182.94 mg) that was dissolved in 10 mL of FC₆H5. The resulting mixture was stirred and a precipitate of LiCl and the desired complex rapidly formed. After 15 minutes the precipitate was collected and washed with 10 mL of FC6H5. The desired complex was extracted from the LiCl precipitate with 100 mL of CH2CI2, filtered, and the remaining solid LiCl discarded. The CH2CI2 solution was concentrated under high vacuum to afford the desired complex in 95% yield (0.95 mmol, 746.3 mg).

[0142] ¾ NMR (300 MHz, CD₂C1₂, 25 ^°C): 6=5.78 (m, 1H), 4.92 (s-br, 2H), 3.74 (s-br, 2H), 3.53 (m, 2H), 1.52 (m, 12H); ^P-^H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C):

6=1 17.61 ; ¹³C MR (100 MHz, CD₂C1₂, 25 ^°C): 6=119.41 , 29.85, 27.17, 22.58; "B-^H- dec) NMR (96 MHz, CD₂C1₂, 25 ^°C): 6= 1.38, -7.48, -9.60 ppm.

[0143] Example 3 - Olefin Polymerization

Polynorbomene

[0144] The catalyst above (0.01 mmol) was dissolved in CH2CI2. Subsequent addition of norbornene (1 mmol) monomer and stirring the mixture for 1 hour, afforded polynorbomene in 82% yield. The polymer was isolated by the addition of methanol to the mixture, whereupon the polymer precipitated.

[0145] Example 4 - Synthesis of a Catalyst

[0146] This catalyst is suitable for use in, for example, olefin hydrogenation

COD

[0147] A solution of the phosphine ligand iPr₂PCBnCln^" Li (x 4 THF) (1 mmol, 933.421 mg) dissolved in 20 mL FC₆¾ was reacted with a solution of (ClIr(COD))₂ (0.5 mmol 335.85 mg) dissolved in 40 mL of FC6H₅. The mixture was stirred for 24 hours and a precipitate of LiCl formed. The solution was filtered and concentrated under high vacuum to afford the desired complex in 100% yield (1.0 mmol, 938.5 mg). Structure was confirmed by single crystal diffraction study and NMR ³¹P-(1H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C): 6=100.54 ppm

[0148] Example 5 - Olefin Hydrogenation

[0149] Procedure: The catalyst above (0.1 mmol) was dissolved in a solution of cyclooctene (2 mmol)/5 mL THF. The mixture was exposed to 1 atmosphere of hydrogen gas and heated to 25°C for 30 minutes. ^XH NMR analysis of the mixture revealed complete hydrogenation of cyclooctene to afford cyclooctane in quantitative yield (2 mmol, 100%).

[0150] Example 6 - Synthesis of a Catalyst

[0151] This catalyst is suitable for use in, for example, olefin polymerization.

COD = 1 ,4-cyclooctadiene

[0152] Synthesis of PdCH₃(COD)iPr₂PCB₁₁H₅Br₆ A solution of iP^PCBnHsBre^" Li⁺ (x 4 THF) (774.78 mg, 1.0 mmol) in THF, was combined with a solution of PdCH₃Cl(COD) (265.1 mg, 1 mmol) in THF and the reaction mixture was allowed to stir for 1 hour. Lithium Chloride was precipitated out by the addition of CHCI₃ and the solution filtered. Volatiles were removed under reduced pressure and washed with hexanes (2 x 2mL). The zwitterionic complex 2 was obtained as a light yellow colored powder (694.82 mg, 98 % yield). ^XH NMR (300 MHz, CD₂C1₂, 25 ^°C): 6=5.89 (m, 2H), 5.39 (m, 2H), 2.68 (m, 4H) 2.54 (m, 4H), 2.38 (m, 2H), 1.48 (m, 12H), 1.31 (s, 3H); ³¹P-(1H-dec) NMR (121 MHz, CD₂C1₂, 25 ^°C):

6 = 68.32

[0153] Example 7 - Olefin Polymerization

spersity

ispersity

[0154] The catalyst above (0.1 mmol) was dissolved in CH₂C1₂. Subsequent addition of monomer (1 mmol) and stirring the mixture for 1 hour, afforded polynorbornene (98% yield) and Polycyclooctene (93% yield), respectively. The polymer was isolated by the addition of methanol to the mixture, whereupon the polymer precipitated. Analysis of the material by Gel permeation chromatography reveals a very low polydispersity of 1.048 (polynorbomene) and 1.056 (polycyclooctene) and an average molecular weight of approximately 12,000. These data indicate that the catalyst is quite active.

[0155] Example 8 - Synthesis of a Catalyst

[0156] This catalyst is suitable for use in, for example, olefin polymerization

COD = 1 ,4-cyclooctadiene

[0157] Synthesis of

[0158] A solution of iPr₂PCB_nH₅Br₆ ^" Li⁺ (x 4 THF) ( 1 (774.78 mg, 1.0 mmol) in THF, was combined with a solution of PdCH₃Cl(COD) (265.1 mg, 1 mmol) in THF and the reaction mixture was allowed to stir for 1 hour. Volatiles were removed under reduced pressure and washed with hexanes (2 x 2mL) to afford the complex in quantitative yield (1 mmol, 1.039 g). ³¹P-(¹H-dec) NMR (121 MHz, THF, 25 ^°C): δ = 71.30 ppm.

[0159] Example 9 - Olefin Polymerization

[0160] The catalyst above (0.1 mmol) was dissolved in THF. Subsequent addition of norbomene (1 mmol) monomer and stirring the mixture for 4 hours, afforded polynorbomene in 95% yield. The polymer was isolated by the addition of methanol to the mixture, whereupon the polymer precipitated. [0161] Example 10 - Synthesis of a Catalyst

[0162] This catalyst is suitable for use in, for example, Pd-catalyzed cross-coupling.

[0163] Synthesis of Pd(iPr₂PCBnH₅Br₆)^2" 2Li⁺(x 4 THF). A solution of iPr₂PCB_uH₅Br₆ Li⁺ (x 4 THF) (774.78 mg, 1.0 mmol) in THF, was combined with a solution of (CH₃)₂Pd (COD) (123.0 mg, 0.5 mmol) in THF and the reaction mixture was allowed to stir for 1 hour. Volatiles were removed under reduced pressure to afford the desired dianionic Pd(0) complex a dark colored (828.0 mg, 100 % yield). The structure was confirmed by a preliminary X-ray diffraction study and NMR. ^P-^H-dec) NMR (121 MHz, THF, 25 ^°C): δ = 53.41 ppm.

[0164] Example 11 - Pd Cross-coupling (alpha arylation of ketones)

[0165] The catalyst above (0.1 mmol) was dissolved in THF. Subsequent addition of the ketone (1 mmol), chlorobenzene (1 mmol) and NaOtBu (1.05 mmol) followed by heating at 80°C for 6 hours, afforded the desired alpha-arylated ketone in 89% yield as indicated by 1H NMR spectroscopy.

[0166] Example 12 - Synthesis of a Catalyst

[0167] This catalyst is suitable for use in, for example, olefin hydrogenation

COD = 1 ,4-cyclooctadiene

[0168] Synthesis of anionic ClIr(COD)[P(C₃H₇)₂CB₁₁H₁₁]: P(C₃H₇)₂(CB₁₁H₁₁)^" N(Butyl)₄ ⁺

(501.6 mg, 1 mmol) in benzene (5 mL) was added to a benzene (5 mL) solution of

(Ir(COD)Cl)2 (335.8 mg, 0.5 mmol) and allowed to stir overnight. The mixture was concentrated under vacuum and washed with hexanes (2 x 5mL), to afford the desired anionic complex as a yellow-orange solid in 100% yield (837.4 mg, lmmol mmol). ³¹P NMR (242 MHz, C₆D₆, 25 ^°C): 6=37.46 ppm.

[0169] Example 13 - Olefin Hydrogenation

[0170] Procedure: The catalyst above (0.1 mmol) was dissolved in a solution of cyclooctene (1 mmol)/5 mL THF. The mixture was exposed to 1 atmosphere of hydrogen gas and heated to 50°C for 2 hours. ^XH NMR analysis of the mixture revealed complete hydrogenation of cyclooctene to afford cyclooctane in quantitative yield (1 mmol, 100%).

[0171] Example 14 - Hydrogenation

[0172] Procedure: The catalyst above (0.1 mmol) was dissolved in a solution of cyclooctene (2 mmol)/5 mL THF. The mixture was exposed to 1 atmosphere of hydrogen gas and heated to 40°C for 1 hour. ^XH NMR analysis of the mixture revealed complete hydrogenation of cyclooctene to afford cyclooctane in quantitative yield (2 mmol, 100%).

[0173] Example 15 - Synthetic Procedure

[0174] This Example shows a synthesis of a phosphine bearing the CBnClif moiety, (iPr)₂P(CBiiClii)^"Li⁺. This group is advantageous because it is very large and the intermediate steric bulk of the isopropyl groups allow the phosphorus lone pair to be accessible for coordination. The trimethyl ammonium salt of anion 1 with 2 (in Figure 1) was treated with equivalents of w-BuLi and subsequent quenched with the dianionic intermediate with ClP(iPr)₂ afforded 2 in 98% yield (Figure 1). Anionic phosphine 2 is very soluble in common polar solvents (CH2CI2, CHCI3, THF), and is not sensitive to oxygen in solution or the solid state. The ^XH NMR of 2 displays two distinct doublets of doublets for the CH₃ isopropyl groups, indicating hindered rotation about the P-iPr bonds. A single crystal X- ray diffraction study shows a sterically congested environment around the pyramidalized (sum of CPC angles = 325.1°) phosphorus center (Figure 2). The phosphorus bond to the carborane hypercarbon (P-Cl = 1.9376(16)A) is significantly longer than the P-iPr bonds (P- C2 = 1.8679(19), P-C3 = 1.8636(18)A). The lithium countercation of 2 is coordinated by four THF molecules and does not associate with the phosphorus lone pair or pendant charged carborane R-group (closest CI distance to Li = 4.283 A). This observation suggests that the phosphorus lone pair is available for binding other metals and that the weakly coordinating nature of the CBnCn R-group remains intact.

[0175] Anionic phosphine 2 (in Figure 1) was reacted with ClAu(THT) in fluorobenzene at RT, and within 5 minutes a large amount of white precipitate formed . Analysis of the precipitate by ³¹P NMR in CD₂CI₂ shows a phosphorus resonance at +90 ppm, which is significantly shifted down field from the starting material 2 (+77 ppm), and in line with the formation of a Au-phosphine complex. The ^XH-NMR spectra clearly shows resonances corresponding to the phosphine ligand as well as coordinated THT, which suggests the formation of the zwitterionic Au complex 3₍THT₎ (Figure 3) formed via ligand coordination and anion metathesis . The driving force for the anion metathesis is the insolubility of LiCl in F-benzene. A single crystal X-ray diffraction study confirms the structure of 3₍THT If the reaction is performed in THF, a solvent where LiCl is soluble, THT is liberated and an unusual anionic ClAu-Li+ complex 3 (LiCl) is isolated. Complex 3 (LiCl) can also be prepared by the treatment of isolated 3(THT) with LiCl in THF. In contrast to 3(THT) it was possible to grow single crystals of 3 (LiCl) without significant disorder and thus examined the solid state structural aspects of this molecule. The Tolman cone angle for the AP -phosphine ligand is 204°, which indicates it is much more bulky than a standard sterically demanding phosphine ligand, such as P(t-Bu)3 (cone angle = 182°). The P-Au bond length is 2.2477(12) A, which is close to a neutral ortho-dicarbaclosodecaborane substituted phosphine AuCl complex (2.232(3) A). The anionic CBnCln R-group displays one chloride interaction with the Au ion (closest Au....Cl-B distance = 3.118 A), which is outside the sum of the covalent Au/Cl radii but in range of a van der Waals contact (sum of Au/Cl vdW radii = 3.41 A). For comparison, the chloride ligand (trans from the phosphine) is at a distance of 2.2883(12) A from the metal center. Hence, the carborane substituent retains a significant amount of weakly coordinating character, even though it is forced into a position close to the metal center.

[0176] Example 16 - Hydroamination

[0177] Table 1. Hydroamination of alkynes with primary amines and catalysts 3 (Figure 3).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

[0178] Yields not in brackets, were measured by NMR via direct integration of the alkyne consumed versus the imine product formed, and reflect the average of two catalytic runs. No side reactions were observed. Number in brackets after the NMR yield indicate isolated yield.

[0179] This Example demonstrates the catalytic properties of complexes 3 in the hydroamination of primary amines with alkynes. This example observed the addition of aniline to phenyl acetylene. A 1 : 1 neat mixture of amine and alkyne was added to 0.1 mol% of complex 3₍ΤΗΤ>, where upon an exothermic reaction occurred. Monitoring the reaction by ^lH NMR revealed the hydroamination was >95% complete in 1 hour (entry 1, Table 1). Identical results were obtained with 3(LiCl), (entry 2, Table 1), hence further catalytic tests were carried out using exclusively 3(THT). Reducing the catalyst loading to 0.01% and heating the mixture at 50°C for 16 hour does not reduce the yield of the imine (entry 3, table 1). Even at a catalyst loading of 0.004%, the imine is formed in excellent yield (88%), which corresponds to a catalyst turn over number (T.O.N.) of 22,000 (entry 4, table 1). The highest reported T.O.N, for the Au-catalyzed hydroamination of an alkyne with a primary amine is around 9000, using a multicomponent acid activated Au system. Control experiments with ClAu(THT), or HCB_nCln-Cs+/ClAuTHT at low catalyst loading (0.1mol%) afforded the imine in only trace amounts (<5%). A metal free Bronsted acid catalyzed pathway can also be ruled out since (iPr)2P(CBnCln)- I¾NPh⁺ does not catalyse the reaction. Since such high catalytic activity is extremely unusual for Au catalyzed reactions, this Example observed the hydroamination of phenyl acetylene with several different aryl amines at ultra-low loading (0.001%, 10 ppm). After 24 hours mesityl amine effectively reacts to afford the

corresponding imine in 67% yield (T.O.N. = 67,000) (entry 5, table 1). Bulkier 2,6- diisopropylphenylamine (Dipp-amine) is even more efficient in the reaction, affording the analogous imine in 85% yield (T.O.N. = 85,000) (entry 6, table 1). For the latter reaction, the catalyst is also fast, displaying an initial Turn Over frequency of 29,000 in the first hour. Even higher T.O.N.s are obtained for the analogous reactions with 4-fluorophenylacetylene, reaching a maximum of 92,000 with Dipp-amine (entries 7-9, table 1). Results with 4- methoxyphenylacetylene were better than most, where the catalyst converted all three amines to the corresponding imines with T.O.N.s of 90,000 or greater (entries 10-12). The trend in increased reactivity with amine steric bulk is likely related to the decreased binding ability of bulkier amines, and the ensuing imines, which allows for more facile ligand exchange at the Au center. Catalyst 3(THT) is also effective for the hydroamination of aryl amines with diaryl substituted (entries 13-15, table 1), and terminal alkyl alkynes (entries 15-18, table 1). Although the activity is lower in these cases the performance of 3(THT) compares favorably with typical Au catalysts, which often require catalyst loadings of l-10mol%. At low catalyst loading (0.2 mol%), and using internal dialkylalkynes (3-hexyne) or an alkyl amine (t- BuNH2) as substrates produced the expected imines only in trace amounts (<5%).

[0180] The two mechanisms generally proposed for Au catalyzed hydroamination either involve a direct addition of the amine to a coordinated alkyne or a coordination insertion mechanism. In either pathway, charged intermediates exist that undergo proton transfer steps that lead to the formation of the functionalized amine. It is clear that the pendant anionic CBnClii group of AP-phosphine 2 is beneficial for the reaction sequence. If industrial scale applications are to be realized for homogenous Au catalysis, as well as systems utilizing other precious metals, it is necessary to have catalysts, such as complexes 3, available that are highly active and efficient. Many transition metal catalyzed processes involve cationic intermediates that might benefit from the use of an AP-ligand.

[0181] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference. Where a conflict exists between the instant application and a reference provided herein, the instant application shall dominate.

Claims

WHAT IS CLAIMED IS:

1. A composition comprising a transition metal and a phosphine lig comprising at least one carba-closo-dodecaborate substituent.

2. A ligand having the following structure:

wherein R¹ is selected from the group consisting of H, halogen, alkyl, aryl, silyl, and alkoxy;

R² and R³ are each independently selected from the group consisting of alkyl, aryl, alkoxy, and NR⁴R⁵; and

R⁴ and R⁵ are each independently selected from the group consisting of alkyl, aryl, and alkoxy; and

A is a cation.

3. A composition comprising:

a solvent selected from the group consisting of dimethoxy ethane, dioxane, pyridine, tetrahydrofuran, diethyl ether, benzene, toluene, acetonitrile, methylene chloride, chloroform, dimethyl formamide, and acetone;

a ligand of claim 2; and

a transition metal selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

4. The composition of claim 3, wherein the transition metal is selected from the group consisting of Fe, Ru, Co, Ni, and Pd.

5. The ligand of claim 2, wherein R¹ is a halogen selected from the group consisting of F, CI, Br, and I.

6. The ligand of claim 2, wherein A is selected from the group consisting of Li, Na, K, Cs, HN(alkyl)₃, N(alkyl)₄, Mg, Ca, and Zn.

7. The ligand of claim 2, wherein R¹ is H.

8. The ligand of claim 2, wherein R is CI.

9. The ligand of claim 2, wherein R is Br.

The ligand of claim 2, wherein R is I.

1 1. The ligand of claim 2, wherein R is alkyl.

The ligand of claim 2, wherein R is alkoxy.

The ligand of claim 2, wherein R is siloxy.

14. The ligand of claim 2, wherein R¹ comprises two or more different types of substituents selected from the group consisting of H, halogen, alkyl, aryl, silyl, and alkoxy.

The ligand of claim 2, wherein R¹ comprises combinations of H and halogen.

The ligand of claim 2, wherein the ligand has a structure selected from the group consisting

A zwitterionic complex having the following structure:

R⁴ and R⁵ are each independently selected from the group consisting of alkyl, aryl, and alkoxy;

X¹ is selected from the group consisting of H, alkyl, aryl, halide, alkoxy, and

NR⁴R⁵;

L is neutral ligand;

subscript n is an integer selected from the group consisting of 1, 2, 3, 4, 5, and

6; and

M is a transition metal.

18. The complex of 17, wherein R² and R³ are isopropyl.

19. The complex of 17, wherein n is 1.

20. The complex of 17, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

21. The complex of claim 20, wherein M is selected from the group consisting of Fe, Ru, Co, Ni, and Pd. A zwitterionic complex having the following structure:

NR⁴R⁵;

Q is a chelating ligand; and

M is a transition metal.

23. The complex of claim 22, further comprising 1 to 2 additional Q chelating ligands bonded to M.

24. The complex of claim 22, wherein R² and R³ are isopropyl.

25. The complex of 22, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

26. The complex of claim 22, wherein M is selected from the group consisting of Fe, Ru, Co, Ni, and Pd.

An anionic complex having the following structure:

X¹ is selected from the group consisting of H, alkyl, and aryl;

X² is an anion selected from the group consisting of H, halide, alkyl, aryl, halide, alkoxy, and R⁴R⁵;

A is a cation;

L is neutral ligand;

6; and

M is a transition metal.

28. The complex of claim 27, wherein n is 1.

29. The complex of 27, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

30. The complex of claim 27, wherein M is selected from the group consisting of Fe, Ru, Co, Ni, and Pd.

31. An anionic complex having the following structure:

X¹ is selected from the group consisting of H, alkyl, and aryl;

Q is a chelating ligand; and

A is a cation; and

M is a transition metal.

32. The complex of claim 31, further comprising 1 to 2 additional Q ligands bonded to M.

33. The complex of claim 31, wherein A is selected from the group consisting of Li, Na, K, Cs, HN(alkyl)₃, and N(alkyl)₄.

34. The complex of 31, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

35. The complex of claim 31, wherein M is selected from the group consisting of Fe, Ru, Co, Ni, and Pd. A zwitterionic complex having the following structure:

L is neutral ligand;

6; and

M is a transition metal.

37. The complex of 36, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

38. The complex of claim 36, wherein M is selected from the group consisting of Fe, Ru, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

39. The complex of 36, wherein n is 1.

A zwitterionic complex having the following structure:

M is a transition metal.

41. The complex of 40, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

42. The complex of claim 40, wherein M is selected from the group consisting of Ni, Pd, and Cu.

43. The complex of claim 40, wherein M is in either a +2 or +4 oxidation state.

An anionic complex having the following structure:

A is a cation;

subscript y is an integer selected from the group consisting of 1 and 2; and M is a transition metal.

45. The complex of 44, wherein A is a monopositively charged cation or a dipositively charged cation.

46. The complex of 44, wherein A is a dipositively charged cation and subscript y is 1.

47. The complex of 44, wherein A is a monopositively charged cation and subscript y is 2.

48. The complex of 44, wherein M is selected from the group consisting of Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, and Au.

49. The complex of claim 44, wherein M is selected from the group consisting of Ni, Pd, and Cu. The complex of claim 44, wherein M is in either a +2 or +4 oxidation state.

51. A complex comprising the ligand of claim 2 and a transition metal.

The complex of claim 51 , wherein the transition metal

53. A complex having the structure selected from the group consisting of :

54. A method of polymerizing olefins, comprising contacting a complex of claim 17, 22, 27, or 31, with reagents suitable for olefin polymerization

55. A method of hydroaddition, comprising contacting a complex of claim

36

A method of cross coupling, comprising contacting a complex of claim

40 or 44.